# Subject Index Volume 64&65

A

Acetaldehyde-induced bronchoconstriction in asthmatics, effect of pranlukast hydrate, 65.41

Adipogenesis markers, expression in murine stromal cell line, 65.216 Aging

cognitive deficits, brain and hippocampus fatty acid composition

paraoxonase and platelet-activating factor acetylhydrolase activities and, 65.241

Airway contractility, effect of dietary n-3 and n-6 polyunsaturated

Alloxan-induced cytotoxicity, protective action of arachidonic acid, 64.37

Angiotensin II, stimulation of PGF2x release via L-type calcium channels, 65.73

Anti-oxidants, vegetarians and non-vegetarians, 64.53 Antidepressants, cancer prevention and treatment, 65.233

Apoptosis, role of dietary polyunsaturated fatty acids, 64.151 Arachidonic acid (AA)

effect of AA-rich oil on lipids and arachidonate metabolites in ethanol-treated rats, 64.273

effects of fatty acyl CoA esters on prostaglandin and arachidonoyl-CoA formed from AA in kidney medulla, 64.61

protective action against alloxan-induced cytotoxicity and diabetes mellitus 64.37

stimulated release by agonists of peroxisome proliferator-activated receptor and retinoic acid receptors, 65.229

stimulated release from rat liver cells by celecoxib and indomethacin. 65.31

tyrosine kinase-phosphorylated protein in arachidonic acid-treated cells, 65.173

Arachidonyl trifluoromethyl ketone induction of lipid body formation in leukocytes, 64.227

Arterial disease, peripheral occlusive, effects of intravenous oxygen on prostacyclin and thromboxane formation, 65.211

adjuvant induced, role of novel derivative pentacyclic triterpene and ω3 fatty acid (Lupeol-EPA), 64.81 see also Rheumatoid arthritis

Aspirin: effect on eicosanoids of low-dose aspirin combined with fish oil, 64.291

6-oxo-PGF<sub>1x</sub> and 8-epi-PGF<sub>2x</sub> in arterial wall layers, 64.167 protective effect of plant sterols, 64.323

Autism: plasma fatty acid levels in autistic children, 65.1

B

Beraprost, effects compared with PGE1, nitroglycerin and nifedipine,

Beta-adrenoceptor antagonist, cyclopsorine A-induced hypertension,

BM-573 activity on platelet function and isolated smooth muscles,

immunohistochemical localization of prostacyclin receptor (IP),

resorption, prostaglandin-induced increase in neonatal mouse calvaria, 64.117

Bone marrow cells, expression of adipogenesis markers, 65.216

Bosentan, improvement of respiratory function in endotoxic shock.

Bradykinin, effect on prostaglandin production in rat vas deferens,

Breastfeeding: association of breastfeeding duration, milk fat composition and developmental indices at one year, 64.105

Bronchoconstriction, acetaldehyde-induced, effect of pranlukast hvdrate, 65.41

C

Calcium, involvement in angiotensin II-induced PGF<sub>2x</sub> release, 65.73 Calcium ATPase activity, effect of essential fatty acid supplementation. 64.147

15-lipoxygenase-1 activity and localization in colorectal carcinoma Caco-2 cells, 64.217

antidepressants and eicosanoids and: review, 65.233

pancreatic, influence of vitamins A, C and E on lipid peroxidation, 65.165

peroxisome proliferator-activated receptor-y expression in malignant and normal cell lines, 241

prostaglandin E2 concentrations in naturally occuring canine cancer, 64.1

role of dietary polyunsaturated fatty acids in preneoplastic urothelial proliferation, 64.151

uptake and metabolic conversion of fatty acids in Hep2 larynx tumor cells, 65.295

Celecoxib, and release of arachidonic acid from rat liver cells, 65.31

Hep2, uptake and metabolic conversion of fatty acids, 65.295 stromal, expression of adipogenesis markers, 65.216

Cognitive deficits, aged-relative, brain and hippocampus fatty acid composition and, 64.189

Colorectal carcinoma, 15-lipoxygenase-1 activity and localization in Caco-2 cells, 64.217

Corticosteroids, effects in glomerular disorders, 65.197

Cyclooxygenase (COX), in streptozotocin-pancreatic damage, 64.311 Cyclooxygenase-2 (COX-2), platelets, 64.299

Cyclooxygenase-2 selective inhibitors, evaluation on purifed ovine enzymes and human whole blood, 64.211 Cyclopsorine A-induced hypertension, nitric oxide in, role of

 $\beta$ -adrenoreceptor antagonist and thromboxane A<sub>2</sub>, 65.259

Cyclosporine A nephrotoxicity, preventive role of prostanoids and endothelins, 64.231

Cysteinyl leukotriene antagonist, effect on acetaldehyde-induced bronchoconstriction in asthmatics, 65.41

Cytotoxicity, alloxan-induced, protective action of arachidonic acid,

15-Deoxy∆S12,14s-prostaglandin J<sub>2</sub>, effect on adipogenesis in stromal cell lines, 65.215

Diabetes mellitus

modulation of PGE2 generation in diabetic embryo, 64.127 protective action of arachidonic acid, 64.37

thromboxane A2 synthesis and expression of procoagulant activity, 65.133

vascular complications, thromboxane/prostacyclin ratio and,

Diet

polyunsaturated fatty acids

effect on insulin sensitivity and lipid metabolism in OLETF rats,

modulation of urothelial proliferation and apoptosis, 64.151 restricted, opioid effects on uterine glucose and eicosanoid metabolism, 65.117

Docosahexaenoic acid (DHA)

effects of eicosapentaenoic acid/docosahexanoic acid in glomerular disorders, 65.197

effects on rat liver and reproductive tissue, 65.23

prevention of activation of cyclin-dependent kinases ad S-phase entry by serum stimulation in HT-29 cells, 64.67

supplementation in essential fatty acid deficiency, effects on cellular fatty acid acyl desaturation, 64.11

Doxorubin-induced damage in cardiomyocytes, counteracting role of -linolenic acid, 64.139

Dyslexia, platelet activating factor and, 64.173

E

Eicosanoids

antidepressants and, cancer prevention and treatment, 65.233 effect of low-dose aspirin combined with fish oil, 64.291

from human saphenous vein endothelial cells, profile and effect of dietary fatty acids, 65.15

metabolism in restricted diet rats, effects of opioids, 65.117 see also specific eicosanoids

Eicosapentaenoic acid (EPA)

attenuation of oxalate-induced nephrotoxicity by eicosapentaenoate-lipoate derivative, 65.265

role of Lupeol-EPA in adjuvant induced arthritis in rats. 64.81 Eicosapentaenoic acid/docosahexanoic acid, effects in glomerular disorders, 65.197

Electrical stimulation, effect on prostaglandin production in rat vas deferens, 65.9

Endothelins

involvement in respiratory centre activity, 65.157

relationship with nitric oxide in intestinal ischemia/reperfusion injury, 64.253

role in prevention of cyclosporine-induced nephrotoxicity, 64.231 Enzyme immunoassay (EIA), measurement of urinary PGE2 in infants. 64.317

Essential fatty acids see under Fatty acids

Exercise: response of muscle interstitial prostaglandin E2, prostacyclin and thromboxane A2 during incremental dynamic exercise determined by in vivo microdialysis, 64.259

F

Fatty acids

brain and hippocampus composition, aged-relative cognitive deficit rats, 64.189

composition, effect of dietary gamma-linolenic acid, 65.205 in composition of milk lipids of Nepalese women, 65.147

dietary, effect on eicosanoids produced by saphenous vein endothelial cells, 65.15

essential deficiency and supplementation with DHA; 22: 6n-3), effects on cellular fatty acid acyl desaturation, 64.11

as mediators of statins, 65.37

modulation of intestinal vitamin D receptor availability and calcium ATPase activity, **64**.147

vegetarians and non-vegetarians, 64.53 plasma levels in autistic children, 65.1

polyunsaturated

dietary, effect on airway contractility, 64.281

dietary, modification of vascular dysfunction in hypertension,

dietary, modulation of urothelial proliferation and apoptosis,

effect of fish-oil supplements in pregnancy on neonatal long-chain polyunsaturated fatty acid status, 65.51

effect on insulin sensitivity and lipid metabolism in OLETF rats,

glucose-insulin-potassium regimen and, effect in lupus and other inflammatory conditions, 65.109

polyunsaturated long-chain, biochemical effects of supplementation in hyperphenylalaninemia, 64.111

role of a novel derivative pentacyclic triterpene and ω3 fatty acid (Lupeol-EPA) in adjuvant induced arthritis, 64.81

uptake and metabolic conversion in Hep2 larynx tumor cells, 65.295

Fatty acyl CoA esters, effects on prostaglandin and arachidonoyl-CoA formed from arachidonic acid in kidney medulla, 64.61

effect on eicosanoids of low-dose aspirin combined with fish oil, 64.291

effect on lipid peroxidation of short-term dietary administration of marginal levels, 64.265

effect of three low-dose supplements in pregnancy on neonatal long-chain polyunsaturated fatty acid status, 65.51

Flavonoids, differential effects on epidermal cytosolic phospholipase A<sub>2</sub>, **65**.281

G

Gamma-linolenic acid, role in counteracting doxorubicin-induced damage in cardiomyocytes, 64.139

Garlic-induced hypotension, possible mechanism, 64.5

Glomerular disorders, effect of corticosteroids and eicosapentaenoic acid/docosahexaenoic acid, 65.197

Glucose metabolism in restricted diet rats, effects of opioids, 65.117 Glucose-insulin-potassium regimen combined with polyunsaturated fatty acids, lupus and other inflammatory conditions, 65.109

Glutathione levels after skeletal muscle ischemia-reperfusion, effects of nitric oxide, 65.179

Growth factors, vascular endothelial, prostaglandin E2 modulation of production in macrophages, 65.123

H

15-Hydroxyprostaglandin dehydrogenase mRNA expression HL60 cells differentiated by PMA, effect of indomethacin, 64.87 murine uterine and gestational tissues in late pregnancy, 64.247

Hyperphenylalaninemia, biochemical effects of supplemented longchain polyunsaturated fatty acids, 64.111

Hypertension

CsA-induced, nitric oxide in: role of ß-adrenoreceptor antagonist and thromboxane A2, 65.259

dietary polyunsaturated fatty acid and modification of vascular dysfunction, 65.91

pulmonary, effects of beraprost, 64.197

thromboxane B2, prostaglandin E2 and hypertension in rat 2kidney 1-clip model, 64.5

Hypotension, garlic-induced, possible mechanism, 64.5

I

Ibuprofen, attenuation of early lung injury in endotoxemic, neutropenic rats, 65.59

Immune function, effect of dietary gamma-linolenic acid, 65.205 Immunohistochemical localization of prostacyclin receptor (IP) in bone, 65.79

Indomethacin

effect on 15-PGDH mRNA expression in HL60 cells differentiated by PMA, 64.87

effects on prostaglandin production by placenta, 64.23 and release of arachidonic acid from rat liver cells. 65.31

Inflammatory disorders, effect of glucose-insulin-potassium regimen combined with polyunsaturated fatty acids, 65.109

Insulin

glucose-insulin-potassium regimen combined with polyunsaturated fatty acids, effect in lupus and other inflammatory conditions. 65.109

sensitivity to, effect of dietary polyunsaturated fatty acid, 64.181 Ischemia, lower limb, effect of revascularisation on leukotriene E4 production, 64.289

Ischemia-reperfusion injury

intestinal, nitric oxide and endothelin relationship in, 64.253 skeletal muscle, effects of nitric oxide following, 65.179

Isoprostanes

6-oxo-PGF<sub>12</sub> and 8-epi-PGF<sub>22</sub> in arterial wall layers, 64.167 8-iso-PGF2x excretion rate, 65.99

increase of 8-epi-PGF2x after restarting smoking, 64.307

transcardiac 8-iso-prostaglandin F<sub>2n</sub> generation from acute myo-cardial infarction heart: marker for oxidant stress, **64**.161

#### K

Kinases, cyclin-dependent, effects of docosahexaenoic acid, 64.67

#### L

Larynx tumor cells Hep2, uptake and metabolic conversion of fatty acids. 65.295

Leukotriene E4 (LTE4)

production, effect of revascularisation of ischaemic lower limb,

urinary, rheumatoid arthritis, 65.301

Linoleic acids

conjugated, effects on rat liver and reproductive tissue, 65.23

dose-dependent effects of dietary gamma-linolenic acid on fatty acid composition and immune parameters, 65.205

Linolenic acid, gamma, role in counteracting doxorubicin-induced damage in cardiomyocytes, 64.139

Lipid body formation in leukocytes, arachidonyl trifluoromethyl ketone and, 64.227

Lipid metabolism, effect of dietary polyunsaturated fatty acid, 64.181 Lipid peroxidation

effects of short-term dietary administration of marginal levels of vitamin B<sub>6</sub> and fish oil, 64.265

microsomes and mitochondria from different rat tissues: effect of retinyl palmitate, 64.75 product levels in bovine retained and not retained placenta, 64.33

Lipids

dietary, airway contractility and, 64.281

effect of arachidonic acid-rich oil in ethanol-treated rats, 64.273 peroxidation

lung surfactant, inhibition by surfactant protein A, 65.185 in pancreatic cancer, influence of antioxidative vitamins, 65.165 Lipoic acid: attenuation of oxalate-induced nephrotoxicity by

eicosapentaenoate-lipoate derivative, 65.265 Lipopolysaccharide, gestational age-dependent effects on prostaglan-

din production, 64.135 15-Lipoxygenase-1 activity and localization in colorectal carcinoma Caco-2 cells, 64.217

Liver

effects of conjugated linoleic acids and docosahexaenoic acid, 65.23

stimulated release of arachidonic acid by celecoxib and indomethacin, 65.31

Lower limb ischaemia, effect of revascularisation on leukotriene E4 production, 64.289

Lung injury, ibuprofen attenuation of early injury, 65.59

Lupeol-EPA, role in relation to lysosomal enzymes, glycoproteins and collagen in adjuvant induced arthritis, 64.81

Lupus erythematosus, effect of glucose-insulin-potassium regimen combined with polyunsaturated fatty acids, 65.109

#### M

Macrophage activation, differential mRNA expression of prostaglandin receptor subtypes, 65.287

Malondialdehyde, effects of nitric oxide after skeletal muscle

ischemia-reperfusion, 65.179 Microdialysis in vivo technique, determination of responses during incremental dynamic exercise, 64.259

Milk, human

fat composition and breastfeeding duration, effect on developmental indices at 1 year, 64.105 fatty acid composition of milk lipids of Nepalese women, 65.147

differential expression, prostaglandin receptor subtypes in macrophage activation, 65.287

expression, cytosolic phospholipase A2 and 15-hydroxyprostaglandin dehydrogenase in uterine and gestational tissues, 247

Muscle, skeletal, effects of nitric oxide after ischemia-reperfusion, 65.179

#### N

Natriuresis, volume-induced, in healthy women, 64.95

Nephrotoxicity

cyclosporine-induced, preventive role of prostanoids and endothelins, 64.231

oxalate-induced, attenuation by eicosapentaenoate-lipoate derivative, 65.265

Nitric oxide

cyclopsorine A-induced hypertension, role of B-adrenoreceptor antagonist and thromboxane A2, 65.259

effect on PGE2 generation in diabetic embryo, 64.127

effects after skeletal muscle ischemia-reperfusion, 65.179 relationship with endothelins in intestinal ischemia/reperfusion

injury, 64.253 in streptozotocin-pancreatic damage, 64.311

Non-steroidal anti-inflammatory drugs (NSAIDs), evaluation on purifed ovine enzymes and human whole blood, 64.211

NS-398, effects on prostaglandin production by placenta, 64.23

## 0

Opioids, effects on uterine glucose and eicosanoid metabolism in restricted diet rats, 65.117

Opunita robusta ingestion, effect on oxidation injury, 65.45 Osteoblasts

characterization of prostaglandin receptors in, 64.203

sphingosine-1-phosphate effects on PKC isoform expression,

Oxalate-induced nephrotoxicity, attenuation by eicosapentaenoatelipoate derivative, 65.265

Oxidant stress, vegetarians and non-vegetarians, 64.53

Oxidation injury effect of opunita robusta ingestion, 65.45

smoking and, 64.307

Oxygen, intravenous, effects on prostacyclin and thromboxane formation in peripheral occlusive arterial disease, 65.211

#### p

Pancreas, streptozotocin-induced damage, inducible isoforms of COX and NOS in, 64.311

Pancreatic cancer, influence of vitamins A, C and E on lipid peroxidation, 65.165

Paraoxonase activity, aging and, 65.241

Peroxidation, lipids see Lipids, peroxidation

Peroxisome proliferator-activated receptor agonists, stimulation of arachidonic acid release, 65.229

Peroxisome proliferator-activated receptor- $\gamma$  expression in malignant and normal cell lines, 241

Phospholipase A2

cytosolic, mRNA expression in murine uterine and gestational tissues in late pregnancy, **64**.247 epidermal cytosolic, differential effects of flavonoids, **65**.281

Phytosterols, dietary, effect on vascular smooth muscle cells, 64.323 Placenta

bovine retained/not retained, lipid peroxidation product levels, 64.33

prostaglandin production, effects of indomethacin, NS-398 and protein synthesis inhibitors, **64**.23

Platelet activating factor, dyslexia and, 64.173

Platelet-activating factor acetylhydrolase activity, aging and, **65**.241 Platelet function, activity of movel thromboxane A<sub>2</sub> receptor antagonist and thromboxane synthase inhibitor, **65**.67

Polyunsaturated fatty acids see under Fatty acids

Potassium: glucose-insulin-potassium regimen combined with polyunsaturated fatty acids, effect in lupus and other inflammatory conditions, 65.109

Pranlukast hydrate, effect on acetaldehyde-induced bronchoconstriction in asthmatics, 65.41

Pregnancy

cytosolic phospholipase A<sub>2</sub> and 15-hydroxyprostaglandin dehydrogenase mRNA expression in murine uterine and gestational tissues in late pregnancy, **64**.247 effects of conjugated linoleic acids and docosahexaenoic acid on

reproductive tissue, 65.23

fish-oil supplements, effect on neonatal long-chain polyunsaturated fatty acid status, 65.51

gestational age-dependent effects of lipopolysaccharide on prostaglandin production, 64.135

Prickly pear see Opunita robusta

Procoagulant activity, expression in diabetes mellitus, 65.133

Propanolol, prevention of cyclopsorine A-induced hypertension, 65,259

Prostacyclin see Prostaglandin I2

Prostaglandin A<sub>2</sub> (PGA<sub>2</sub>): tyrosine kinase-phosphorylated protein in PGA<sub>2</sub>-treated cells, **65**.173

Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>)

concentrations in naturally occuring canine cancer, 64.1

effects of nitric oxide on  $PGE_2$ -like activity after skeletal muscle ischemia-reperfusion,  ${\bf 65.179}$ 

modulation of generation in diabetic embryo, 64.127

modulation of vascular endothelial growth factor production in macrophages, 65.123

muscle interstitial, response in dynamic exercise determined by in vivo microdialysis, **64**.259

receptors, differential mRNA expression in macrophage activation,  ${\bf 65.}287$ 

thromboxane- $B_2$ , prostaglandin  $E_2$  and hypertension in rat 2-kidney 1-clip model, **64**.5

urinary concentrations measured by new EIA method in infants, 64.317

Prostaglandin  $F_2$  (PGF<sub>2</sub>): determination of  $9\alpha$ ,118-PGF<sub>2</sub> in urine by combined solid-phase extraction and radioimmunoassay, **65**.271 Prostaglandin  $F_{2\alpha}$  (PGF<sub>2 $\alpha$ </sub>)

angiotensin-induced release via L-type calcium channels,  $\bf 65.73$  metabolite (15-keto-dihydro-PGF $_{2a}$ ) excretion rate,  $\bf 65.99$ 

Prostaglandin I2 (PGI2; prostacyclin)

analysis of urinary prostacyclin and thromboxane/prostacyclin ratio in rheumatoid arthritis, 65.85

effect of  $PGI_2$  analogue on progression rate of renal dysfunction,  $\mathbf{65.223}$ 

formation in peripheral occlusive arterial disease, effects of intravenous oxygen, 65.211

immunohistochemical localization of receptor (IP) in bone, **65**.79 muscle interstitial, response in dynamic exercise determined by in vivo microdialysis, **64**.259

renal metabolism in volume-induced natriuresis, 64.95

TXA<sub>2</sub>/prostacyclin ratio and diabetic vascular complications, **65**,191

Prostaglandins

biosynthesis in dispersed choriodecidual cells in culture, **65**.247 effect of bradykinin and electrical stimulation on production in rat vas deferens, **65**.9

effects of fatty acyl CoA esters on formation in kidney medulla, 64.61

induction of bone resorption in neonatal mouse calvaria, **64**.117 production by murine decidual caps, gestational age-dependent effects of lipopolysaccharide, **64**.135

production by placenta: effects of indomethacin, NS-398 and protein synthesis inhibitors, **64**.23

receptors, characterization in osteoblasts, 64.203

see also Isoprostanes

Prostanoids

pharmacology of IP prostanoid receptors in NCB-20 cells, **65**.253 physiological role in volume-induced natriuresis, **64**.95 role in prevention of cyclosporine-induced nephrotoxicity, **64**.231

Protein synthesis inhibitors, effects on prostaglandin production by placenta, **64**.23

#### R

Radioimmunoassay combined with solid-phase extraction, determination of  $9\alpha$ , 11ß-PGF $_2$  in urine, 65.271

Renal insufficiency, effect of  $PGI_2$  analogue on progression rate of renal dysfunction, 65.223

Reproductive tissue, effects of conjugated linoleic acids and docosahexaenoic acid, 65.23

Respiratory system mechanics, endothelin and, 65.157

Retinoic acid receptor agonists, stimulation of arachidonic acid release, 65.229

Retinyl palmitate, effect on lipid peroxidation of microsomes and mitochondria from different rat tissues, 64.75

Rheumatoid arthritis

analysis of urinary prostacyclin and thromboxane/prostacyclin ratio,  ${\bf 65.}85$ 

urinary 11-dehydro TXB2 and LTE4 excretion, 65.301

#### S

Saphenous vein endothelial cells, profile of eicosanoids produced and effect of dietary fatty acids, **65**.15

Shock, endotoxic, bosentan and, 65.103

Smoking, effect of restarting on isoprostane 8-epi-PGF<sub>2α</sub>, **64**.307

Smooth muscles, activity of novel thromboxane A<sub>2</sub> receptor antagonist and thromboxane synthase inhibitor, **65**.67

Sphingosine-1-phosphate (SIP) effects on PKC isoform expression in osteoblasts, 65.139

Statins, essential fatty acids as mediators of action, 65.37

Stone formation, inhibition by eicosapentaenoate-lipoate derivative,  ${\bf 65.}265$ 

Streptozotocin-induced pancreatic damage, inducible isoforms of COX and NOS in, 64.311

Superoxide dismutase, effect on PGE<sub>2</sub> generation in diabetic embryo, **64** 127

Surfactant: surfactant protein A inhibition of lipid peroxidation of lung surfactant, 65.185

## T

Thromboxane

formation in peripheral occlusive arterial disease, effects of intravenous oxygen, 65.211

- renal metabolism in volume-induced natriuresis, 64.95
- Thromboxane A2 (TXA2)
- cyclopsorine A-induced hypertension, **65**.259
- muscle interstitial, response in dynamic exercise determined by in vivo microdialysis, 64.259
- synthesis in diabetes mellitus, 65.133
- TXA<sub>2</sub>/prostacyclin ratio and diabetic vascular complications, 65 191
- Thromboxane  $A_2$  receptor antagonist, novel, activity on platelet function and isolated smooth muscles, **65**.67
- Thromboxane B2 (TXB2)
  - thromboxane-B<sub>2</sub>, prostaglandin E<sub>2</sub> and hypertension in rat 2-kidney 1-clip model, **64**.5
- urinary 11-dehydro TXB2 in rheumatoid arthritis, 65.301
- Tyrosine kinase-phosphorylated protein in arachidonic acid- and prostaglandin A<sub>2</sub>-treated cells, **65**.173

## v

- Vascular dysfunction, modulation in hypertension, dietary polyunsaturated fatty acid and, 65.91
- Vascular endothelial growth factor, prostaglandin E<sub>2</sub> modulation of production in macrophages, **65**.123
- production in macrophages, **65**.123 Vascular smooth muscle cells, effect of plant sterols, **64**.323
- Vegetarians: oxidant stress, anti-oxidants and essential fatty acids in vegetarians and non-vegetarians, **64**.53
- Vitamin B<sub>6</sub>, effect on lipid peroxidation of short-term dietary administration of marginal levels, **64**.265
- Vitamin D receptor availability modulation due to EFA supplementation, effect on calcium retention, **64**.147
- Vitamins: influence of vitamins A, C and E on lipid peroxidation in pancreatic cancer, 65.165

## **Author Index**

#### A

Abeywardena, M.Y., 64.281; 65.91 Abo, M., 65.41 Agnoli, D.C., 64.95 Agostoni, C., 64.105, 111 Aitken, H., 64.23 Aktan, A.Ö., 64.253 Al-Qattan, K.K., 64.5 Alaniz, M.J.T. de, 65.295 Albertini, M., 65.103, 157 Albino, L., 65.295 All, M., 64.5 Allen, K.G.D., 65.23 Alnaqeeb, M.A., 64.5 Ampatzidis, G., 64.259 Andrès, C., 65.1 Angelopoulou, N., 64.259 Awad, A.B., 64.233

#### B

Babül, A., 65.179 Barthélémy, C., 65.1 Basu, S., 65.99 Baudoin, C., **64**.87 Bergami, R., **64**.265 Beusekom, C.M. van, 65.51 Bhatt, S.K., 65.147 Biagi, P.L., 64.139 Bianchi, P.C., 65.173 Bkaily, G., 64.203 Blanco, O., 65.185 Blanqué, R., 64.117 Bonvissuto, M., 64.111 Bordoni, A., **64**.139 Borgatti, R., **64**.95 Bozza, P.T., 64.227 Bravo, M.G. de, 65.295 Brum-Fernandes, A.J. de, 64.203 Bruzzese, M.G., 64.111 Budinsky, A., 65.45 Budinsky, A.C., 64.307

#### C

Cabrini, L., 64.265
Cacciari, M., 64.95
Campos, M.L., 65.117
Capello, J.J., 65.51
Capoblanco, E., 64.127
Carloni, A., 64.265
Casalino-Matsuda, S.M., 65.117
Catalá, A., 64.75; 65.185
Celuch, S.M., 65.9
Chalon, S., 65.1
Che, Z.-Y., 64.67
Chehne, F., 64.307
Chiba, S., 65.301
Christoulas, K., 64.259

Chuang, L-T., **65**.147 Ciminaghi, B., **65**.103, 157 Clement, M.G., **65**.103, 157 Coffman, K., **64**.1 Cornicelli, J.A., **64**.217 Cottereaux, C., **64**.117 Cremonezzi, D.C., **64**.151 Crider, J.Y., **65**.253 Cuzzolin, L., **64**.317

#### D

Dagli, T.E., 64.253 Daphtary, K.M., 65.59 Darlametsos, I.E., 64.231 Das, U.N., 64.37, 53; 65.37, 109, 197 David, J.-L., 64.211 de Alaniz, M.J.T., 65.295 de Bravo, M.G., 65.295 De Brum-Fernandes, A.J., 65.79 de Leval, X., 64.211 Delarge, J., **64**.211; **65**.67 DeNicola, D.B., **64**.1 Devel, P., 64.211 Dick, J.R., 64.11 Dijs, F.P.L. van der, 65.51 Dogné, J.-M., 64.211 Dogné, J.M., **65**.67 Du Toit, P.J., **65**.173 Dumais, R., 64.203 Durakbaşa, Ç.U., **64**.253 Durand, G., **65**.1 Dziak, R., 65.139

## E

Efthimiou, Y., **65**.45 Eling, T.E., **64**.217 Endo, M., **65**.223 Engström, K., **64**.291 Erickson, K.L., **65**.123, 287 Eynard, A.R., **64**.151

#### F

Fanos, V., **64**.317 Fink, C.S., **64**.323 Fortier, I., **65**.79 Frenkian, M., **64**.87 Frölich, J.C., **65**.211 Fujimoto, Y., **64**.61 Fujimura, M., **65**.41 Fujita, T., **64**.61; **65**.223 Fuke, Y., **65**.223 Fukunaga, M, **64**.161

G

Galli, C., **64**.105 Garcia Palacios, V., **65**.215 Gardner, C.R., 64.117 Cimeno, M.A.F., 64.127; 65.115 Giovannini, M., 64.105, 111 Glew, R.H., 65.147 Glibetic, M., 65.59 Glickman, N.W., 64.1 Goldraij, A., 65.117 González, E., 64.311 Gonzalez, E.T., 64.127 Guilloteau, D., 65.1 Gupta, D.K., 64.135, 247 Guski, H., 65.165 Gutzki, F-M., 65.211

#### H

Haag, M., 64.147 Haché, R., **64**.203 Haklar, G., **64**.253 Hansen, R.A., 65.23 Harris, M.A., 65.23 Hashimoto, T., 65.41 Hashimura, K., 64.161 Hasuda, K., 64.181 Havek, M.G., 64.1 Head, R.J., 64.281; 65.91 Heidemann, S.M., 65.59 Helmersson, J., 65.99 Henrotin, Y., 64.211 Hidaka, M., 65.223 Hishinuma, T., 65.85, 191, 301 Hrelia, S., 64.139 Hsi, L.C., 64.217 Huang, Y-S., 65.147 Hubbard, N.E., 65.123, 287

#### I

Inoue, H., **65**.85, 301 Ishii, K., **64**.181 Istfan, N.W., **64**.67

J

Jablonskis, L.T., **64**.281 Jacobi, C.A., **65**.165 Jagt, D.J. vander, **65**.147 Jagt, T.A. vander, **65**.147 Jawerbaum, A., **64**.127, 311 Joubert, A.M., **65**.173 Joubert, F., **65**.173 Jullienne, A., **64**.87

#### K

Kaku, S., **65**.205 Kamer, A., **65**.139 Kamio, Y., **65**.41 Kamitani, H., **64**.217 Kaneyuki, T., **64**.273 Kankofer, M., **64**.23 Karamazouzis, I., **64**.259 Karamazouzis, M., **64**.259 Katayama, N., **65**.41 Kato, Y., **64**.161 Katoh, Y., **64**.61 Keelan, J.A., **64**.135, 247 Khalil, A., **65**.241 Khan, I., **64**.5 Kijima, Y., **64**.161 Kilian, M., 65.165 Kim, H.P., 65.281 Kita, T., 65.41 Kita, T., 65.41 Kitao, A., 64.61 Klis, F.R.M. van der, 65.51 Komatsu, K., 65.223 Konieczkowski, M., 65.133 Koslo, J.L., 65.23 Kreutzer, F.J., 65.211 Krishna Mohan, I., 65.197 Kritz, H., 64.167 Kruger, M.C., 64.147 Kubota, M., 64.181 Kurumatani, H., 64.197 Kuukasjärvi, P., 64.289

#### I.

Lafortuna, C.L., 65.157 Lammardo, A.M., 64.105 Lampasso, J.D., 65.139 Landman, H., 65.51 Latha, R.M., 64.81 Lee, S-H., 65.287 Lejeune, B., 65.1 Lenin, M., 64.81; 65.265 Lenzi, P., 64.95 Leonard, F., 64.147 Leval, X. de, 64.211 Levine, L., 65.31, 229 Lieb, J., 65.233 Lim, D., 65.287 Linares, J.A., 65.117 Lora, M., 65.79 Lottering, M-L., **65**.173 Lupattelli, G., **64**.307

#### M

Magnussen, M.A., 65.147 Mandroukas, K., 64.259 Mangiarotti, P., 64.317 Manjari, V., 64.53 Maranesi, M., 64.265 Marangoni, F., **64**.105 Marchetti, M., **64**.265 Margarone, J. III, 65.139 Marinelli, M., 64.95 Martineau, J., 65.1 Marvin, K.W., 64.247; 65.247 Masereel, B., 65.67 Matsumoto, F., 65.85, 301 Matsushita, T., 64.197 Matsu-ura, Y., 64.161 Mazzola, S., **65**.103, 157 Michaux, C., **64**.211; **65**.67 Milochevitch, C., 65.241 Mimouni, V., 64.189 Mitchell, M.D., 64.135, 247; 65.247 Mitomo, T., 65.85, 301 Mizugaki, M., 65.85, 191, 301 Mohammed, S.I., 64.1 Morita, I., 65.215 Mucha, R., 65.271 Mukutmoni, M., 65.123 Müller, J.M., 65.165 Murota, S., **65**.215 Muskiet, F.A.J., **65**.51 Myou, S., 65.41

N

Nagaraj, M., **65**.265 Nakamura, H., **65**.85, 301 Nakao, S., **65**.41 Neven, P., **64**.211 Nicolaou, A., **65**.15 Nishitsuji, M., **65**.41 Nomura, S., **65**.41 Nonaka, M., **65**.205 Nowak, V., **65**.211 Nwankwo, J.O., **64**.241

0

Oguogho, A., **64**.167, 307; **65**.45 Ohi, H., **65**.223 Ohkura, K., **65**.205 Ohsawa, I., **65**.223 Ohta, Y., **64**.273 Okita, M., **64**.181, 273 Oriji, G.K., **65**.73, 259 Orita, Y., **64**.161 Ota, Y., **64**.181

P

Palacios, A., 64.75 Palumbo, B., 64.307 Panzer, A., 65.173 Parkin, S.M., 65.15 Patry, C., **64**.203; **65**.79 Peralta, C., **65**.115 Peredo, H.A., 65.9 Pham, H.T., 65.281 Pidoux, E., 64.87 Piergiacomi, V.A., 64.75 Pilar Díaz, M.del, 64.151 Pirotte, B., 64.211 Poisson, J.-P., 64.189 Polo, M.P., 65.295 Porsolt, R., 64.189 Poyser, N.L., **64**.23 Pustovrh, C., 64.127; 65.115

R

Rasool, M., **64**.81 Ravi Raju, T., **65**.197 Reiter, R., **64**.299 Resch, U., **64**.299 Richardson, A.J., **64**.173 Ridders, J., **65**.165 Riutta, A., **64**.289; **65**.271 Riva, E., **64**.105, 111 Robbins, M.E.C., **64**.241 Rocha, F.A.C., **64**.203 Rolin, S., **65**.67 Roselló-Catafau, J., **64**.311 Rossi, P., **64**.289 Roux, S., **64**.189

S

Sailaja Devi, M.M., **64**.53 Sakuma, S., **64**.61 Saldeen, T., **64**.291 Salenius, J.P., **64**.289 Samadfan, R., 65.79 Sarrazin, P., 64.203 Sasagawa, T., 64.181, 273 Sato, T.A., 64,135, 247 Satomura, A., 65.223 Sawai, T., 65.85, 301 Sayan, H., 65.179 Scaglioni, S., 64.111 Schanz, N., **65**.259 Schimke, I., **65**.165 Schlittler, D., 64.1 Seegers, J.C., 65.173 Segond, N., 64.87 Sharif. N.A., 65.253 Silva, R.A., **64**.151 Sinner, D., **64**.127; **65**.115 Sinzinger, H., 64.167, 299, 307; 65.45 Skrinska, V.A., 65.133 Smith, A.J., 64.323 Stahlknecht, P., 65.165 Stamatopoulos, Y., 65.45 Stein, J.F., 64.173 Stichentoth, D.O., 65.211 Stipo, L., **64**.95 Sugano, M., **65**.205 Suresh, Y., 64.37, 53 Suzuki, K., 64.273; 65.191 Suzuki, N., 65.301

T

Tachibana, H., **65**.205 Takabatake, M., **65**.301 Tamura, M., **64**.197 Taylor, K.E., **64**.173 Thiagarajan, A., **65**.265 Thomas, J.B., **65**.23 Tocher, D.R., **64**.11 Tolomelli, B., **64**.265 Tsikas, D., **65**.211 Tsukamoto, H., **65**.191, 301

U

Ueda, T., **64**.161 Ugurlu, B., **65**.179 Ulmann, L., **64**.189 Urquhart, P., **65**.15

V

Valentich, M.A., **64**.151 Vamvakoudis, E., **64**.259 Van Beusekom, C.M., **65**.51 Van der Dijs, F.P.L., **65**.51 Vancassel, S., **65**.1 Van der Klis, F.R.M., **65**.51 Vander Jagt, D.J., **65**.147 Vander Jagt, T.A., **65**.147 Varalakshmi, P., **64**.81; **65**.265 Varonos, D.D., **64**.231 Vela, J., **65**.115 Velzing-Aarts, F.V., **65**.51 Vidsudhiphan, P., **65**.23

W

Wagner, O., **64**.167 Wallin, R., **64**.291 Waters, D.J., **64**.1 Watkins, B.A., **65**.23 Weller, P.F., **64**.227 Wenger, F.A., **65**.165 White, V., **64**.127; **65**.115 Wolfram, R., **65**.45

X

Xaus, C., **65**.115 Xu, S.X., **65**.253 Y
Yamada, K., **65**.205
Yasuda, T., **64**.161
Yoshimi, Y., **65**.41
Yüksel, M., **64**.253
Yunoki, S., **65**.205

Ziboh, V.A., 65.281



